263410-12-4

Basic information

• Product Name: tert-butyl 2-bromoethylmethylcarbamate
• Synonyms: tert-butyl 2-bromoethylmethylcarbamate;(2-Bromo-ethyl)-methyl-carbamic acid tert-butyl ester
• CAS NO: 263410-12-4
• Molecular Formula: C₈H₁₆BrNO₂
• Molecular Weight: 238.13
• Mol File: 263410-12-4.mol

Chemical Properties

• Boiling Point: 244.6±19.0 °C(Predicted)
• Appearance: /
• Density: 1.290±0.06 g/cm3(Predicted)
• PKA: -1.54±0.70(Predicted)
• CAS DataBase Reference: tert-butyl 2-bromoethylmethylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-bromoethylmethylcarbamate(263410-12-4)
• EPA Substance Registry System: tert-butyl 2-bromoethylmethylcarbamate(263410-12-4)

Safety Data

• Hazardous Substances Data: 263410-12-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
tert-Butyl 2-bromoethylmethylcarbamate is used as a synthetic intermediate for the preparation of cyclic amino-pyrazinecarboxamide compounds. These compounds have potential applications in the development of pharmaceuticals, particularly as therapeutic agents for various diseases and conditions.
Used in Chemical Synthesis:
In the field of chemical synthesis, tert-butyl 2-bromoethylmethylcarbamate is utilized as a versatile reagent to produce a range of different organic compounds. Its unique structure allows it to participate in various chemical reactions, contributing to the formation of new molecules with diverse properties and applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 57561-39-4 methyl(2-hydroxyethyl)carbamic acid tert-butyl ester 

Downstream Products

• 1051929-53-3 tert-butyl 2-(4-((5-(2-methoxybenzylcarbamoyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)piperidin-1-yl)ethyl(methyl)carbamate 

Relevant articles and documents

Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents

On the basis of deguelin, a series of the B,C-ring truncated surrogates with N-substituted amide linkers were investigated as HSP90 inhibitors. The structure activity relationship of the template was studied by incorporating various substitutions on the nitrogen of the amide linker and examining their HIF-1α inhibition. Among them, compound 57 showed potent HIF-1α inhibition and cytotoxicity in triple-negative breast cancer lines in a dose-dependent manner. Compound 57 downregulated expression and phosphorylation of major client proteins of HSP90 including AKT, ERK and STAT3, indicating that its antitumor activity was derived from the inhibition of HSP90 function. The molecular modeling of 57 demonstrated that 57 bound well to the C-terminal ATP-binding pocket in the open conformation of the hHSP90 homodimer with hydrogen bonding and pi-cation interactions. Overall, compound 57 is a potential antitumor agent for triple-negative breast cancer as a HSP90 C-terminal inhibitor.

AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.

CONJUGATES OF THE B-SUBUNIT OF SHIGA TOXIN FOR ANTICANCER THERAPIES

Conjugates or pharmaceutical compositions comprising conjugates of the B-subunit of Shiga toxin that are useful for cancer therapies are disclosed. More specifically, the pharmaceutical compositions comprise STxB conjugated to at least one antimitotic age

Conjugates of the B-subunit of Shiga toxin for anticancer therapies

Conjugates or pharmaceutical compositions comprising conjugates of the B-subunit of Shiga toxin that are useful for cancer therapies are disclosed. More specifically, the pharmaceutical compositions comprise STxB conjugated to at least one antimitotic agent such as auristatin or pharmaceutically acceptable salts thereof through a bifunctional linker. Processes to make the conjugates, as well as methods to treat cancers are also disclosed.

SHIGA TOXIN B-SUBUNIT/CHEMOTHERAPEUTICS CONJUGATES

The present invention relates to the use of a Shiga toxin B-subunit moiety as carrier for therapeutic agents, for example, anti-cancer agents such as anti-cancer agents that require intracellular uptake to exert their anti-cancer effects. In particular, the present invention provides conjugates comprising a Shiga toxin moiety covalently linked to an anti-cancer agent through a self-immolative spacer, and methods of using such conjugates to increase cellular uptake and/or specificity for cancer cells of the anti-cancer drug. Also provided are methods of treatment involving administration of such conjugates, and pharmaceutical compositions and kits useful for carrying out such methods of treatment.

Shiga toxin-mediated retrograde delivery of a topoisomerase I inhibitor prodrug

(Figure Presented) A retrograde strategy: An innovative cancer-cell delivery concept exploits the naturally evolved characteristics of the Shiga toxin B-subunit (STxB) for the intracellular activation of a newly synthesized prodrug at the level of the bio